Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

# Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December. **Read the full article:** [CNBC](https://www.cnbc.com/2026/02/03/pfizer-pfe-earnings-q4-2025.html) *This article was originally published by CNBC. MoneyWiseInc provides expert curation of the best financial content from trusted sources.*